TYMS anticorps

N° du produit ABIN3026351

Détail du produit anti-TYMS anticorps

Antigène: TYMS (Thymidylate Synthetase (TYMS))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp TYMS est non-conjugé

Application: Immunofluorescence (IF), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Attributs du produit: This antibody is specific for a protein of 36 kDa, identified as Thymidylate Synthase (TS). Thymidylate synthase converts deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), which is essential for DNA biosynthesis. Thymidylate synthase is also a critical target for the fluoropyrimidines, an important group of anti-neoplastic drugs that are widely used in the treatment of solid tumors. Both 5-FU and fluorodeoxyuridine are converted in tumor cells to FdUMP which inactivates thymidylate synthase by formation of a ternary covalent complex in the presence of the folate cofactor 5,10-methylenetetrahydrofolate. Expression of thymidylate synthase protein is associated with response to 5-fluorouracil (5-FU) in human colorectal, gastric, head and neck, and breast carcinomas.

Purification: Protein G purified monoclonal antibody

Immunogène: Recombinant human Thymidylate synthase was used as the immunogen for this antibody.

Clone: TMS715

Isotype: IgG1 kappa

Information d'application

Indications d'application: The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the antibody to be titered up or down for optimal performance.

1. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10  mM Citrate Buffer,  pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. FACS: 0.5-1 μg/million cells,IF: 0.5-1 μg/mL,IHC (FFPE): 0.5-1 μg/mL for 30 minutes at RT (1),Prediluted format : incubate for 30 min at RT (2)

Restrictions: For Research Use only

Stockage

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store the Thymidylate Synthase antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Détails sur TYMS

Antigène: TYMS (Thymidylate Synthetase (TYMS))

Autre désignation: Thymidylate Synthase (TYMS Produits)

Synonymes: anticorps FN1, anticorps ECK2823, anticorps JW2795, anticorps ts, anticorps Ts, anticorps HST422, anticorps TMS, anticorps TS, anticorps thymidylate synthetase, anticorps contains intron in T4 phage, anticorps ThyE, anticorps thymidylate synthase, anticorps thymidylate synthetase L homeolog, anticorps TYMS, anticorps thyA, anticorps td, anticorps thyE, anticorps DDA3937_RS04960, anticorps tyms.L, anticorps XBJ1_RS15770, anticorps EAMY_RS20680, anticorps Tyms

Classe de substances: Viral Protein

Sujet: This antibody is specific for a protein of 36  kDa, identified as Thymidylate Synthase (TS). Thymidylate synthase converts deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), which is essential for DNA biosynthesis. Thymidylate synthase is also a critical target for the fluoropyrimidines, an important group of anti-neoplastic drugs that are widely used in the treatment of solid tumors. Both 5-FU and fluorodeoxyuridine are converted in tumor cells to FdUMP which inactivates thymidylate synthase by formation of a ternary covalent complex in the presence of the folate cofactor 5,10-methylenetetrahydrofolate. Expression of thymidylate synthase protein is associated with response to 5-fluorouracil (5-FU) in human colorectal, gastric, head and neck, and breast carcinomas.

ID gène: 7298

Pathways: Mitotic G1-G1/S Phases